Quest Diagnostics (DGX), the Fortune 500 diagnostics services provider, has made strategic developments over the recent period. It has advanced
access to transplant services while continuing to declare
quarterly cash dividends. Various appointments such as welcoming the FedEx CIO to its board and nominating Murali Balakumar as the Senior VP and Chief Information and Digital Officer, shows operational growth. Despite fluctuating stock performance, DGX consistently reported that it outperformed competitors. The company's expansion in
digital pathology,
drug testing and
partnerships (with ReproSource, Broad Clinical Labs, etc.) shows its intent to capture a larger market share. DGX's recent
acquisitions of select assets highlight its growth strategy. Analyst EPS projections aligning with the company's Q1 2024 earnings and an increase in sales mark a positive financial performance.
Q4 2024 EPS, however, is estimated to have lowered. With consistent efforts towards
innovation, Quest has launched various tests and services like the MelaNodal Predict™ Test and mobile phlebotomy service. An impressive
62% return over the last five years has pleased investors. Regulatory approvals for its new tests further portray a positive outlook.
Quest Diagnostics DGX News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Sun, 19 May 2024 10:51:52 GMT -
Rating 8
- Innovation 2
- Information 8
- Rumor 2
